NCT03578354

4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine

Prospective, Randomized, Placebo-controlled, Phase 2 Study of 4-aminopyridine, Atenolol, or Placebo in the Treatment of Patients With Vestibular Migraine

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Massachusetts Eye and Ear Infirmary · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This phase 2 randomized study will be used to test the efficacy of 4-aminopyridine (4AP) or atenolol to reduce severity and frequency of vestibular and headache symptoms of vestibular migriane sufferers. Blinded study drug will be taken by mouth twice a day for 14 weeks on study.

Conditions

• Vestibular Migraine
• Migraine Disorders
• Vestibular Diseases

Interventions

Type	Name	Description
DRUG	4-aminopyridine	an oral drug to be swallowed
DRUG	Atenolol	an oral drug to be swallowed
OTHER	Placebo	a masked placebo to be swallowed

Timeline

• Start date: 2019-01-01
• Primary completion: 2023-01-01
• Completion: 2024-08-01
• First posted: 2018-07-06
• Last updated: 2024-07-01

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study